§360e–1 — Title 21 Food and Drugs | U.S. Code

Summary

Applicants must include two pieces of information when they send certain device applications or development plans to the Secretary under sections 360j(m) or 360e: a simple description of any pediatric groups who have the disease the device is meant to treat, diagnose, or cure, and the number of affected pediatric patients, if that information is readily available. Not later than 18 months after September 27, 2007, and annually after that, the Secretary must report to the Senate Committee on Health, Education, Labor, and Pensions and the House Committee on Energy and Commerce. The report must cover eight things, including counts of devices approved that year affecting pediatric groups, devices used in children but not labeled for them where labeling could help, humanitarian-use pediatric devices, devices labeled for children, devices exempted from fees, review times for these categories, and how often adult data or data from one pediatric group were used to support use in other pediatric groups. The Secretary may decide adult data are enough when the disease and device effects are similar in adults and children, and a study may not be needed in every pediatric group if one group’s data can be used for another. Pediatric subpopulation: see section 360j(m)(6)(E)(ii) for its definition.

Title 21, §360e–1

Food and Drugs — Source: USLM XML via OLRC

(a)(1)A person that submits to the Secretary an application under section 360j(m) of this title, or an application (or supplement to an application) or a product development protocol under section 360e of this title, shall include in the application or protocol the information described in paragraph (2).

(2)The application or protocol described in paragraph (1) shall include, with respect to the device for which approval is sought and if readily available—

(A)a description of any pediatric subpopulations that suffer from the disease or condition that the device is intended to treat, diagnose, or cure; and

(B)the number of affected pediatric patients.

(3)Not later than 18 months after September 27, 2007, and annually thereafter, the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report that includes—

(A)the number of devices approved in the year preceding the year in which the report is submitted, for which there is a pediatric subpopulation that suffers from the disease or condition that the device is intended to treat, diagnose, or cure;

(B)any information, based on a review of data available to the Secretary, regarding devices used in pediatric patients but not labeled for such use for which the Secretary determines that approved pediatric labeling could confer a benefit to pediatric patients;

(C)the number of pediatric devices that receive a humanitarian use exemption under section 360j(m) of this title;

(D)the number of devices approved in the year preceding the year in which the report is submitted, labeled for use in pediatric patients;

(E)the number of pediatric devices approved in the year preceding the year in which the report is submitted, exempted from a fee pursuant to section 379j(a)(2)(B)(v) of this title;

(F)the review time for each device described in subparagraphs (A), (C), (D), and (E);

(G)the number of devices for which the Secretary relied on data with respect to adults to support a determination of a reasonable assurance of safety and effectiveness in pediatric patients; and

(H)the number of devices for which the Secretary relied on data from one pediatric subpopulation to support a determination of a reasonable assurance of safety and effectiveness in another pediatric subpopulation.

(b)(1)If the course of the disease or condition and the effects of the device are sufficiently similar in adults and pediatric patients, the Secretary may conclude that adult data may be used to support a determination of a reasonable assurance of effectiveness in pediatric populations, as appropriate.

(2)A study may not be needed in each pediatric subpopulation if data from one subpopulation can be extrapolated to another subpopulation.

(c)For purposes of this section, the term “pediatric subpopulation” has the meaning given the term in section 360j(m)(6)(E)(ii) of this title.

Notes & Related Subsidiaries

Editorial Notes

Amendments

2017—Subsec. (a)(3). Pub. L. 115–52 added subpars. (B), (C), (G), and (H), redesignated former subpars. (B) to (D) as (D) to (F), respectively, substituted “(C), (D), and (E);” for “(B), and (C).” in subpar. (F), and inserted concluding provisions.

Statutory Notes and Related Subsidiaries

Final Rule Relating to Tracking of Pediatric Uses of Devices Pub. L. 112–144, title VI, § 620(b),

July 9, 2012, 126 Stat. 1064, provided that: “The Secretary of Health and Human Services shall issue— “(1) a proposed rule implementing section 515A(a)(2) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360e–1(a)(2)) not later than

December 31, 2012; and “(2) a final rule implementing such section not later than

December 31, 2013.”

§360e–1 Pediatric uses of devices